Systemic therapy for Asian patients with advanced BRAF V600‐mutant melanoma in a real‐world setting: A multi‐center retrospective study in Japan (B‐CHECK‐RWD study)

Autor:	Kenjiro Namikawa, Takamichi Ito, Shusuke Yoshikawa, Koji Yoshino, Yukiko Kiniwa, Shuichi Ohe, Taiki Isei, Tatsuya Takenouchi, Hiroshi Kato, Satoru Mizuhashi, Satoshi Fukushima, Yosuke Yamamoto, Takashi Inozume, Yasuhiro Fujisawa, Osamu Yamasaki, Yasuhiro Nakamura, Jun Asai, Takeo Maekawa, Takeru Funakoshi, Shigeto Matsushita, Eiji Nakano, Kohei Oashi, Junji Kato, Hisashi Uhara, Takuya Miyagawa, Hiroshi Uchi, Naohito Hatta, Keita Tsutsui, Taku Maeda, Taisuke Matsuya, Hiroto Yanagisawa, Ikko Muto, Mao Okumura, Dai Ogata, Naoya Yamazaki
Jazyk:	angličtina
Rok vydání:	2023
Předmět:	Asian BRAF immune‐checkpoint inhibitor melanoma targeted therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Zdroj:	Cancer Medicine, Vol 12, Iss 17, Pp 17967-17980 (2023)
Druh dokumentu:	article
ISSN:	2045-7634
DOI:	10.1002/cam4.6438
Popis:	Abstract Background Anti‐PD‐1‐based immunotherapy is considered a preferred first‐line treatment for advanced BRAF V600‐mutant melanoma. However, a recent international multi‐center study suggested that the efficacy of immunotherapy is poorer in Asian patients in the non‐acral cutaneous subtype. We hypothesized that the optimal first‐line treatment for Asian patients may be different. Methods We retrospectively collected data of Asian patients with advanced BRAF V600‐mutant melanoma treated with first‐line BRAF/MEK inhibitors (BRAF/MEKi), anti‐PD‐1 monotherapy (Anti‐PD‐1), and nivolumab plus ipilimumab (PD‐1/CTLA‐4) between 2016 and 2021 from 28 institutions in Japan. Results We identified 336 patients treated with BRAF/MEKi (n = 236), Anti‐PD‐1 (n = 64) and PD‐1/CTLA‐4 (n = 36). The median follow‐up duration was 19.9 months for all patients and 28.6 months for the 184 pa tients who were alive at their last follow‐up. For patients treated with BRAF/MEKi, anti‐PD‐1, PD‐1/CTLA‐4, the median ages at baseline were 62, 62, and 53 years (p = 0.03); objective response rates were 69%, 27%, and 28% (p
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/7bd38e76e920444a8356acd6025d9a4c Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.